Socioeconomic inequities in access to innovative biologic drugs for rheumatic disease in Europe

Tuesday 3 May 2016, 1.00PM to 2.00pm

Speaker(s): Polina Putrik, Erasmus Exchange Fellow, Maastricht University School for Public Health and Primary Care

Abstract: Rheumatic and musculoskeletal diseases (RMDs) are highly prevalent and cause substantial disability burden according to the Global Burden of Diseases report. While socioeconomic inequality in health and health care has risen high on policy agendas across the world in recent years, relatively little research on socio-economic inequalities has been done in the field of RMDs. In rheumatoid arthritis, innovative biologic therapies became available about two decades ago and have proven to improve dramatically the disease activity and function in RA patients and have been included in official treatment recommendations by European League Against Rheumatism (EULAR). However, these therapies are costly with an annual price varying from 10,000 to 20,000 euro per patient. The high cost of these drugs raises concerns about their accessibility to those who need them and about the contribution of this to health disparities.

The purposes of this talk are to:

1) present current research on the role of socio-economic factors in the epidemiology of RMDs, and

2) present data on socioeconomic inequalities of access to innovative treatments in RA on national level and across 46 countries in the European Region

Location: ARRC Auditorium A/RC/014

Who to contact

For more information on these seminars, contact:

Maria Jose Aragon
Jessica Ochalek

CHE Seminar Programme

  • Thursday 12 January 2017
    Jon Sussex, Chief Economist, RAND Europe
  • Thursday 9 February 2017
    Richard Murray, Kings Fund